Elucidating value: the role of cost-effectiveness analysis in the decision-making process for the management of BRAF V600E/K mutation-positive melanoma

被引：1
作者：
Petrou, P. [1 ]
机构：
[1] Univ Nicosia, Pharm Sch, Sch Sci & Engn, Pharmacoepidemiol Pharmacovigilance, Nicosia, Cyprus
来源：
JOURNAL OF MEDICAL ECONOMICS | 2019年 / 22卷 / 12期
关键词：
DABRAFENIB; TRAMETINIB;
D O I：
10.1080/13696998.2019.1674064
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：1241 / 1242
页数：2
相关论文
共 9 条
[1]   Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada [J].
Delea, Thomas E. ;
Amdahl, Jordan ;
Wang, Alice ;
Amonkar, Mayur M. ;
Thabane, Marroon .
PHARMACOECONOMICS, 2015, 33 (04) :367-380
[2]   Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro [J].
Dummer, R. ;
Hauschild, A. ;
Lindenblatt, N. ;
Pentheroudakis, G. ;
Keilholz, U. .
ANNALS OF ONCOLOGY, 2015, 26 :V126-V132
[3]   Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective [J].
Gerbasi, Margaret E. ;
Stellato, Daniel ;
Ghate, Sameer R. ;
Ndife, Briana ;
Moynahan, Aaron ;
Mishra, Dinesh ;
Gunda, Praveen ;
Koruth, Roy ;
Delea, Thomas E. .
JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (12) :1243-1252
[4]   Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma [J].
Long, G. V. ;
Hauschild, A. ;
Santinami, M. ;
Atkinson, V. ;
Mandala, M. ;
Chiarion-Sileni, V. ;
Larkin, J. ;
Nyakas, M. ;
Dutriaux, C. ;
Haydon, A. ;
Robert, C. ;
Mortier, L. ;
Schachter, J. ;
Schadendorf, D. ;
Lesimple, T. ;
Plummer, R. ;
Ji, R. ;
Zhang, P. ;
Mookerjee, B. ;
Legos, J. ;
Kefford, R. ;
Dummer, R. ;
Kirkwood, J. M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19) :1813-1823
[5]   Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial [J].
Long, Georgina V. ;
Stroyakovskiy, Daniil ;
Gogas, Helen ;
Levchenko, Evgeny ;
de Braud, Filippo ;
Larkin, James ;
Garbe, Claus ;
Jouary, Thomas ;
Hauschild, Axel ;
Grob, Jean-Jacques ;
Chiarion-Sileni, Vanna ;
Lebbe, Celeste ;
Mandala, Mario ;
Millward, Michael ;
Arance, Ana ;
Bondarenko, Igor ;
Haanen, John B. A. G. ;
Hansson, Johan ;
Utikal, Jochen ;
Ferraresi, Virginia ;
Kovalenko, Nadezhda ;
Mohr, Peter ;
Probachai, Volodymr ;
Schadendorf, Dirk ;
Nathan, Paul ;
Robert, Caroline ;
Ribas, Antoni ;
DeMarini, Douglas J. ;
Irani, Jhangir G. ;
Swann, Suzanne ;
Legos, Jeffrey J. ;
Jin, Fan ;
Mookerjee, Bijoyesh ;
Flaherty, Keith .
LANCET, 2015, 386 (9992) :444-451
[6]   A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-mutated melanoma in the Swiss setting [J].
Matter-Walstra, K. ;
Braun, R. ;
Kolb, C. ;
Ademi, Z. ;
Dummer, R. ;
Pestalozzi, B. C. ;
Schwenkglenks, M. .
BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (06) :1462-1470
[7]   The quest for the in medio stat virtus price in the oncology sector [J].
Petrou, Panagiotis .
JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (10) :1023-1025
[8]   Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib [J].
Robert, Caroline ;
Karaszewska, Boguslawa ;
Schachter, Jacob ;
Rutkowski, Piotr ;
Mackiewicz, Andrzej ;
Stroiakovski, Daniil ;
Lichinitser, Michael ;
Dummer, Reinhard ;
Grange, Florent ;
Mortier, Laurent ;
Chiarion-Sileni, Vanna ;
Drucis, Kamil ;
Krajsova, Ivana ;
Hauschild, Axel ;
Lorigan, Paul ;
Wolter, Pascal ;
Long, Georgina V. ;
Flaherty, Keith ;
Nathan, Paul ;
Ribas, Antoni ;
Martin, Anne-Marie ;
Sun, Peng ;
Crist, Wendy ;
Legos, Jeff ;
Rubin, Stephen D. ;
Little, Shonda M. ;
Schadendorf, Dirk .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (01) :30-39
[9]  
Surveillance Epidemiology and End Results Program, 2017, CANC STAT FACTS MEL
1